BlueMar Capital Management LLC acquired a new position in PRA Health Sciences, Inc. (NASDAQ:PRAH) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 15,000 shares of the company’s stock, valued at approximately $827,000.

A number of other institutional investors have also recently bought and sold shares of PRAH. US Bancorp DE purchased a new position in PRA Health Sciences during the third quarter worth about $106,000. Fuller & Thaler Asset Management Inc. purchased a new position in PRA Health Sciences during the third quarter worth about $124,000. Pacad Investment Ltd. increased its position in PRA Health Sciences by 22.7% in the fourth quarter. Pacad Investment Ltd. now owns 2,700 shares of the company’s stock worth $149,000 after buying an additional 500 shares during the period. Pacer Advisors Inc. purchased a new position in PRA Health Sciences during the third quarter worth about $152,000. Finally, First Bank & Trust purchased a new position in PRA Health Sciences during the fourth quarter worth about $171,000.

Institutional Ownership by Quarter for PRA Health Sciences (NASDAQ:PRAH)

PRA Health Sciences, Inc. (NASDAQ:PRAH) traded up 0.16% during midday trading on Thursday, reaching $61.08. The company had a trading volume of 308,945 shares. PRA Health Sciences, Inc. has a 1-year low of $38.23 and a 1-year high of $61.39. The firm has a 50-day moving average of $57.04 and a 200 day moving average of $54.38. The company has a market capitalization of $3.75 billion, a P/E ratio of 47.42 and a beta of 0.54.

“BlueMar Capital Management LLC Acquires New Stake in PRA Health Sciences, Inc. (PRAH)” was published by Watch List News and is owned by of Watch List News. If you are reading this news story on another publication, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this news story can be viewed at http://www.watchlistnews.com/bluemar-capital-management-llc-acquires-new-stake-in-pra-health-sciences-inc-prah/1121085.html.

Several equities analysts have recently weighed in on PRAH shares. TheStreet upgraded PRA Health Sciences from a “hold” rating to a “buy” rating in a report on Monday, November 14th. Credit Suisse Group restated a “hold” rating and set a $50.00 price target on shares of PRA Health Sciences in a report on Thursday, November 3rd. Jefferies Group LLC raised their price target on PRA Health Sciences from $63.00 to $66.00 and gave the company a “buy” rating in a report on Tuesday, January 24th. Zacks Investment Research downgraded PRA Health Sciences from a “buy” rating to a “hold” rating in a report on Wednesday, November 9th. Finally, KeyCorp restated a “buy” rating on shares of PRA Health Sciences in a report on Friday, November 4th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. PRA Health Sciences presently has a consensus rating of “Buy” and an average price target of $59.57.

About PRA Health Sciences

PRA Health Sciences, Inc is a contract research organization (CRO). The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

5 Day Chart for NASDAQ:PRAH

Want to see what other hedge funds are holding PRAH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PRA Health Sciences, Inc. (NASDAQ:PRAH).

Receive News & Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.